US FDA Grants Rare Pediatric Disease Designation (RPDD) to Paxalisib for Diffuse Intrinsic Pontine Glioma (DIPG)
SYDNEY, Aug. 7, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA;NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Australia Health | Biotechnology | Brain Tumor | Cancer & Oncology | Clinical Trials | Food and Drug Administration (FDA) | Glioma | Grants | Pediatrics | Pharmaceuticals | USA Health